GlassScriptPhysician profile
Jennifer Copper
NPI 1669882742
$3,682.14
in general payments reported to CMS, 2019-2025
30 companies · $915 in 2025
The $915 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $375 · 2022: $497 · 2023: $1,012 · 2024: $882 · 2025: $915.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,810.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,809.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $989.35 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $692.69 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Shield Therapeutics INC | $447.51 | 2023-2025 | Accrufer |
| Astrazeneca Pharmaceuticals LP | $297.73 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $259.22 | 2021-2025 | Jardiance, Ofev, Tradjenta |
| Abbvie INC. | $187.52 | 2022-2025 | |
| Pfizer INC. | $126.03 | 2021-2025 | |
| Abbott Laboratories | $65.53 | 2022-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $55.32 | 2025 | Rexulti |
| Exact Sciences Corporation | $55.27 | 2023-2024 | Cologuard Collection Kit |
| Dexcom, INC. | $54.66 | 2024-2025 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $38.83 | 2021 | |
| Glaxosmithkline, LLC. | $37.66 | 2021-2022 | |
| Axsome Therapeutics, INC. | $36.74 | 2025 | Auvelity |
| Radius Health, INC. | $35.41 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $32.13 | 2025 | |
| Merck Sharp & Dohme LLC | $29.38 | 2021-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Lundbeck LLC | $24.02 | 2025 | Rexulti |
| Avanos Medical | $23.31 | 2023 | Trivisc Sodium Hyaluronate |
| Scynexis, INC. | $23.07 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.14 | 2024 | |
| Daiichi Sankyo INC. | $20.73 | 2021 | |
| Astellas Pharma US INC | $18.99 | 2023 | Veozah |
| Amgen INC. | $18.62 | 2022 | |
| Sanofi-Aventis U.S. LLC | $17.10 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.48 | 2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $16.08 | 2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $16.06 | 2023 | Xarelto |
| Vericel Corporation | $15.31 | 2022 | |
| Reprise Biomedical, INC. | $10.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Copper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.